Share 1 Print August 03, 2017 07:30 ET | Source: Insmed Incorporated On Track to Report Top-Line Results from Phase 3 CONVERT Study in September plus or minus one month Plan to Initiate Enrollment of Phase 2 Dose-ranging Study of INS1007 in Non-Cystic Fibrosis (non-CF) Bronchiectasis in the Second Half of 2017 U.S. Food and Drug Administration (FDA) Provides Established Name for Lead Development Program – ALIS (amikacin liposome inhalation suspension) BRIDGEWATER, N.J., Aug. 03, 2017 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the unmet needs of patients with rare diseases, today reported financial results for the second quarter ended June 30, 2017 and provided a business update.
Business Update
On track to report top-line results from phase 3 CONVERT study in September plus or minus one month.
